Parker Waichman LLP

FDA Hearing Will Solicit Input on Clinical Trial Transparency

Next month, the Food and Drug Administration (FDA) will hold a public hearing about maintaining confidentiality of preliminary drug trial results until the trials are completed so as not to adversely affect the trial. Cardiovascular outcomes trials (CVOTs) are undertaken to address outstanding regulatory concerns about the safety of an approved drug. The FDA has traditionally […]

FDA-Hearing-Will-Solicit-Input-on-Clinical-Trial-TransparencyNext month, the Food and Drug Administration (FDA) will hold a public hearing about maintaining confidentiality of preliminary drug trial results until the trials are completed so as not to adversely affect the trial.

Cardiovascular outcomes trials (CVOTs) are undertaken to address outstanding regulatory concerns about the safety of an approved drug. The FDA has traditionally required drug makers to conduct additional clinical trials to assess those risks prior to approval. But clinical trials are costly and take years to complete, so in the last ten years, the FDA has increasingly shifted trials to the postmarket, allowing a company to market a drug on the condition that mandatory trials are completed by specified dates, according to the Regulatory Affairs Professional Society (RAPS).

Large CVOTs assess the risks of heart attacks, strokes, or death as a condition of approval.  CVOTs are common for certain classes of drugs, including diabetes medications, and three diabetes drugs – Afrezza, Farxiga, and Tanzeum –recently received approval on condition that the CVOTs be conducted, RAPS reports.

During a trial, drug companies regularly conduct interim analyses to generate preliminary findings. But preliminary findings have sometimes affected ongoing trials. “Sponsors and other interested parties with access to interim data may have difficulty managing the remainder of the trial in an objective manner,” according to the FDA. For this reason the FDA recommends that an Independent Data Monitoring Committee (DMC) review the interim results instead of trial investigators. But the Federal Food, Drug and Cosmetic Act (FD&C Act) calls for summaries of the interim data in postmarket studies to “be made available immediately for public disclosure,” according to RAPS, making it difficult to keep investigators from seeing, and possibly being influenced by, interim data.

In the Federal Register, the FDA says it wants to solicit input on how and when to disclose data to the public, and whether alternative trial designs might be appropriate for use in postmarket settings, RAPS reports.

 

 

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
Outstanding service!
Pamela Carter
5 years ago
5 Star Reviews 150
On the Christmas Eve of 2015 I had a car accident I felt lost and confused. I had no idea what I was going to do or how I was going to get my car fixed. My supervisor referred me Jorge Peniche who works for Parker Waichman. He came to meet me at my house the same day I spoke to him and helped me till the end of my case. I was very pleased with the lawyers and Jillian was very helpful in the process, her and Jorge were ready to answer any of my questions. Thank you Parker and Waichman!!
Fanta Jondot
5 years ago
5 Star Reviews 150
I am very pleased with the outcome of the case. I will never be hesitant to recommend your firm.
Marian Hampton
8 years ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038